NCT03832751UnknownNot Applicable
Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Cairo University
- Enrollment
- 25
- Primary Endpoint
- Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
Study Overview
Brief Summary
There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Patients with non-segmental vitiligo.
- •Both genders.
- •Age more than 18 years old.
- •New cases or cases not receiving any treatment for at least 3 months prior to the study.
Exclusion Criteria
- •Universal or segmental vitiligo.
- •Any contraindication to phototherapy treatment.
- •History of autoimmune diseases or other systemic diseases.
- •Any other skin disease.
Arms & Interventions
vitiligo patients
Experimental
Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
Intervention: skin biopsy before and after NB-UVB phototherapy (Other)
Healthy controls
Active Comparator
Tissue levels of human beta-defensin 1 in healthy controls
Intervention: skin biopsy before and after NB-UVB phototherapy (Other)
Outcomes
Primary Outcomes
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
Time Frame: 6 months to 1 year
Secondary Outcomes
No secondary outcomes reported
Investigators
Maha Fathy Elmasry
principal investigator
Cairo University
Similar Trials
Unknown
Not Applicable
Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid?Bullous PemphigoidNCT03636763Assistance Publique Hopitaux De Marseille183
Completed
Phase 2
Hepatitis B Vaccination (HBV) in HIV Infected ChildrenHIV InfectionsNCT00886964The HIV Netherlands Australia Thailand Research Collaboration80
Not yet recruiting
Not Applicable
Serum Elafin and Vascular Affection in Behcet DiseaseBehcet Disease and Vascular AffectionNCT06272929Assiut University90
Completed
Not Applicable
Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)Recessive Dystrophic Epidermolysis BullosaNCT01874769Institut National de la Santé Et de la Recherche Médicale, France30
Completed
Not Applicable
Pan-immune-inflammation Value (PIN) in Behçet's Disease and Its Correlation With Disease ActivityBehcet SyndromeNCT06729112Assiut University80